Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots

Bruin, Erwin de; Loeber, J.G.; Meijer, Adam; Castillo, G. Martinez; Cepeda, Martha; Torres-Sepúlveda, Maria R; Borrajo, Gustavo; Casini, Michèle; Giguere, Y.; Meyer, Maxence; Fukushi, Masaru; Devi, Anju; Khneisser, Issam; Vilarinho, Laura; Döbeln, U. von; Torresani, T.; Mackenzie, John S.; Zutt, Ilse; Schipper, Maarten; Elvers, L.H.

doi:10.1016/j.jcv.2014.06.020

Cited by 12 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To obtain more insights into the role and development of cross-reactive antibodies and their potential role in the observed immune protection against A(H1N1)2009, we used a protein microarray (PA) to dissect antibody reactivity profiles for seasonal and pandemic influenza A strains (Baas et al, 2013;de Bruin et al, 2014;Freidl et al, 2015;Koopmans et al, 2012). We analysed paired serum samples from children aged 9-10 years, collected shortly before and just after the 2009 pandemic.…”

Section: Introductionmentioning

confidence: 99%

Influenza virus A(H1N1)2009 antibody-dependent cellular cytotoxicity in young children prior to the H1N1 pandemic

Mesman

Westerhuis

Hulscher

et al. 2016

Journal of General Virology

View full text Add to dashboard Cite

Pre-existing immunity played a significant role in protection during the latest influenza A virus H1N1 pandemic, especially in older age groups. Structural similarities were found between A(H1N1)2009 and older H1N1 virus strains to which humans had already been exposed. Broadly cross-reactive antibodies capable of neutralizing the A(H1N1)2009 virus have been implicated in this immune protection in adults. We investigated the serological profile of a group of young children aged 9 years (n=55), from whom paired blood samples were available, just prior to the pandemic wave (March 2009) and shortly thereafter (March 2010). On the basis of A(H1N1)2009 seroconversion, 27 of the 55 children (49 %) were confirmed to be infected between these two time points. Within the non-infected group of 28 children (51 %), high levels of seasonal antibodies to H1 and H3 HA1 antigens were detected prior to pandemic exposure, reflecting past infection with H1N1 and H3N2, both of which had circulated in The Netherlands prior to the pandemic. In some children, this reactivity coincided with specific antibody reactivity against A(H1N1)2009. While these antibodies were not able to neutralize the A(H1N1)2009 virus, they were able to mediate antibody-dependent cellular cytotoxicity (ADCC) in vitro upon interaction with the A(H1N1)2009 virus. This finding suggests that cross-reactive antibodies could contribute to immune protection in children via ADCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Influenza virus A(H1N1)2009 antibody-dependent cellular cytotoxicity in young children prior to the H1N1 pandemic

Mesman

Westerhuis

Hulscher

et al. 2016

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…The study of complete disease dynamics is not something that has yet gained significant traction among field epidemiologists. However, with better access to time-stratified serological collections ( Wu et al, 2011, 2014; de Bruin et al, 2014 ) and new high-throughput serological assays ( Koopmans et al, 2011; Baas et al, 2013; Huijskens et al, 2013 ), these types of studies may become more common. Public health benefits of SSE-like study designs include the ability to distinguish a large influenza epidemic from a severe influenza epidemic.…”

Section: Discussionmentioning

confidence: 99%

Statistical identifiability and sample size calculations for serial seroepidemiology

Vinh

Boni

2015

Epidemics

View full text Add to dashboard Cite

show abstract

“…When coupled with low volume sampling methods, MDA has the potential to vastly increase subject sampling numbers for population based studies, while simultaneously yielding comprehensive data regarding IgG reactivity against multiple influenza strains. For example, a 2014 study used a protein microarray to monitor the trends of the 2009 influenza A (H1N1) pdm virus in 13 countries from five continents by screening bloodspots [78]. Similarly, a new technique called volumetric absorptive microsampling (VAMS), which provides for accurate sampling of a fixed blood volume (10 or 20 µL) on a volumetric swab and allows for long-term sample storage, has been used for peripheral blood sampling [94].…”

Section: Population Studies With Micro-sampling Techniquesmentioning

confidence: 99%

A Complex Dance: Measuring the Multidimensional Worlds of Influenza Virus Evolution and Anti-Influenza Immune Responses

2019

View full text Add to dashboard Cite

The human antibody response to influenza virus infection or vaccination is as complicated as it is essential for protection against flu. The constant antigenic changes of the virus to escape human herd immunity hinder the yearly selection of vaccine strains since it is hard to predict which virus strains will circulate for the coming flu season. A “universal” influenza vaccine that could induce broad cross-influenza subtype protection would help to address this issue. However, the human antibody response is intricate and often obscure, with factors such as antigenic seniority or original antigenic sin (OAS), and back-boosting ensuring that each person mounts a unique immune response to infection or vaccination with any new influenza virus strain. Notably, the effects of existing antibodies on cross-protective immunity after repeated vaccinations are unclear. More research is needed to characterize the mechanisms at play, but traditional assays such as hemagglutinin inhibition (HAI) and microneutralization (MN) are excessively limited in scope and too resource-intensive to effectively meet this challenge. In the past ten years, new multiple dimensional assays (MDAs) have been developed to help overcome these problems by simultaneously measuring antibodies against a large panel of influenza hemagglutinin (HA) proteins with a minimal amount of sample in a high throughput way. MDAs will likely be a powerful tool for accelerating the study of the humoral immune response to influenza vaccination and the development of a universal influenza vaccine.

show abstract

Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots

Abstract: We conclude that this uniform serological testing of samples from a highly standardized screening system offers an interesting opportunity for monitoring population level attack rates of widespread diseases outbreaks and pandemics.

Cited by 12 publications

References 23 publications

Influenza virus A(H1N1)2009 antibody-dependent cellular cytotoxicity in young children prior to the H1N1 pandemic

Influenza virus A(H1N1)2009 antibody-dependent cellular cytotoxicity in young children prior to the H1N1 pandemic

Statistical identifiability and sample size calculations for serial seroepidemiology

A Complex Dance: Measuring the Multidimensional Worlds of Influenza Virus Evolution and Anti-Influenza Immune Responses

Contact Info

Product

Resources

About